×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Module 5: Phase 3 and Regulatory Review
Session Chair(s)
Stephen V. O'Quinn, PharmD
President
Perissos, Inc., United States
- Pivotal Efficacy and Safety Studies
- Serious Adverse Effects
- Long-Term Safety
- Drug-Drug Interactions
- Special Populations
- Carcinogenicity Studies
Have an account?